iSpecimen (NASDAQ:ISPC) Announces Earnings Results

iSpecimen (NASDAQ:ISPC) released its earnings results on Monday. The company reported ($0.48) earnings per share for the quarter, Zacks reports. iSpecimen had a negative return on equity of 395.15% and a negative net margin of 172.48%.

iSpecimen Trading Down 7.5%

iSpecimen stock opened at $0.58 on Tuesday. iSpecimen has a 1-year low of $0.55 and a 1-year high of $4.90. The firm’s fifty day simple moving average is $1.04 and its 200-day simple moving average is $1.07. The company has a market capitalization of $5.67 million, a P/E ratio of -0.06 and a beta of 1.77.

Institutional Trading of iSpecimen

An institutional investor recently bought a new position in iSpecimen stock. Scientech Research LLC purchased a new position in shares of iSpecimen Inc. (NASDAQ:ISPC) in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 29,488 shares of the company’s stock, valued at approximately $38,000. Scientech Research LLC owned approximately 0.30% of iSpecimen as of its most recent filing with the SEC. 13.62% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

ISPC has been the topic of several research analyst reports. Wall Street Zen upgraded shares of iSpecimen to a “sell” rating in a research report on Saturday, September 6th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of iSpecimen in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has a consensus rating of “Sell”.

About iSpecimen

iSpecimen Inc provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide. Its cloud-based technology enables scientists to search for specimens and patients across a network of hospitals, clinics, private practice groups, laboratories, blood centers, biobanks, clinical research sites, and cadaveric donation centers.